MPM Bioimpact LLC Purchases New Stake in Design Therapeutics, Inc. (NASDAQ:DSGN)

MPM Bioimpact LLC acquired a new position in shares of Design Therapeutics, Inc. (NASDAQ:DSGN) in the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor acquired 559,547 shares of the company’s stock, valued at approximately $3,452,000. MPM Bioimpact LLC owned about 0.99% of Design Therapeutics at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of the company. Driehaus Capital Management LLC bought a new stake in shares of Design Therapeutics during the fourth quarter valued at about $4,788,000. BNP Paribas Financial Markets acquired a new stake in Design Therapeutics in the 4th quarter valued at about $249,000. Northern Trust Corp boosted its position in shares of Design Therapeutics by 15.2% during the 4th quarter. Northern Trust Corp now owns 388,125 shares of the company’s stock valued at $2,395,000 after purchasing an additional 51,351 shares in the last quarter. Dimensional Fund Advisors LP grew its stake in shares of Design Therapeutics by 60.2% in the 4th quarter. Dimensional Fund Advisors LP now owns 215,265 shares of the company’s stock worth $1,328,000 after purchasing an additional 80,905 shares during the last quarter. Finally, Walleye Capital LLC raised its holdings in shares of Design Therapeutics by 101.6% in the 4th quarter. Walleye Capital LLC now owns 141,127 shares of the company’s stock worth $871,000 after purchasing an additional 71,127 shares in the last quarter. 56.64% of the stock is currently owned by institutional investors.

Design Therapeutics Price Performance

DSGN stock opened at $3.57 on Wednesday. The firm has a market cap of $202.67 million, a PE ratio of -4.20 and a beta of 1.77. Design Therapeutics, Inc. has a 12 month low of $2.60 and a 12 month high of $7.77. The firm has a 50 day simple moving average of $3.98 and a 200 day simple moving average of $4.93.

Design Therapeutics (NASDAQ:DSGN) last announced its quarterly earnings data on Wednesday, May 14th. The company reported ($0.31) EPS for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.03). As a group, sell-side analysts expect that Design Therapeutics, Inc. will post -0.91 earnings per share for the current year.

Design Therapeutics Company Profile

Design Therapeutics, Inc a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion.